title: Highlights from the new drug session at the Biennial International Congress On Schizophrenia Research, April 2-6, 2011.
abstract: The 2011 International Congress on Schizophrenia Research, held in Colorado Springs, Colorado, attracted nearly 1,200 attendees to the Broadmoor Hotel from 2-6 April 2011, not to mention the satellite meetings on cognition and the schizophrenia prodrome. With the gracious assistance of Congress directors Carol Tamminga and Chuck Schulz, as well as meeting staff Dorothy Denton and Cristan Tamminga, we bring you the following report on the Congress' "New Drug Session: Advances in Medication Development and Assessment."
authors.affiliation: Schizophrenia Research Forum, Brain and Behavior Research Foundation, Providence, RI, USA. hakon@schizophreniaforum.org
authors.forename: Hakon
authors.initials: H
authors.lastname: Heimer
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015507:Drugs, Investigational; D006801:Humans; D018722:Nicotinic Agonists; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D015507:Drugs, Investigational; D018722:Nicotinic Agonists; D018094:Receptors, Metabotropic Glutamate